Reviparin sodium: Difference between revisions

Reviparin sodium
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	B01AB08 (WHO) ;
Identifiers
CAS Number	9005-49-6 ;
DrugBank	DB09259 ;
ChemSpider	none;
UNII	5R0L1D739E;
KEGG	D03337 ;
CompTox Dashboard (EPA)	DTXSID301010914 ;
ECHA InfoCard	100.110.590
	(what is this?) (verify)

Browse history interactively

← Previous edit

Content deleted Content added

VisualWikitext

Inline

Latest revision as of 23:58, 29 January 2023

Reviparin is an antithrombotic and belongs to the group of low molecular weight heparins (LMWH).

Medical uses[edit]

Prevention of blood clots
Prophylaxis of perioperative thromboembolism^[1]^[2]
Treatment of DVT with or without pulmonary embolism (PE)^[3]
Prophylaxis of acute thrombotic events after percutaneous transluminal coronary angioplasty (PTCA)^[4]^[5]

Chemistry[edit]

Reviparin is a low molecular weight heparin obtained by nitrous acid depolymerization of heparin extracted from porcine intestinal mucosa. Its structure is characterized, for the most part, by a group of 2-O-sulfo-α-lidopyranosuronic acid. The average molecular weight is about 3900 daltons.

References[edit]

^ Kakkar VV, Cohen AT, Mohamed MS (1996). "Patients at risk of venous thromboembolism--clinical results with reviparin". Thromb. Res. 81 (2 Suppl): S39–45. doi:10.1016/0049-3848(95)00228-6. PMID 8822126.
^ Lassen MR, Backs S, Borris LC, Kaltoft-Sørenson M, Coff-Ganes H, Jeppesen E (1999). "Deep-vein thrombosis prophylaxis in orthopedic surgery: hip surgery". Semin. Thromb. Hemost. 25 Suppl 3: 79–82. PMID 10549720.
^ Gore M, Kelkar P, Rege N, Ross C (October 2004). "Reviparin sodium clivarine: a review of its therapeutic use". J Indian Med Assoc. 102 (10): 589–90, 592. PMID 15887830.
^ Preisack MB, Karsch KR (December 1993). "Experimental and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary angioplasty". Blood Coagul. Fibrinolysis. 4 Suppl 1: S55–8, discussion S59–60. PMID 8180331.
^ Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R (November 1996). "Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation". J. Am. Coll. Cardiol. 28 (6): 1437–43. doi:10.1016/s0735-1097(96)00343-9. hdl:1765/55740. PMID 8917255.

External links[edit]

reviparin at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Yusuf S, Mehta SR, Xie C, et al. (2005). "Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation". JAMA. 293 (4): 427–35. doi:10.1001/jama.293.4.427. PMID 15671427.

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.

[pmid8822126-1] Kakkar VV, Cohen AT, Mohamed MS (1996). "Patients at risk of venous thromboembolism--clinical results with reviparin". Thromb. Res. 81 (2 Suppl): S39–45. doi:10.1016/0049-3848(95)00228-6. PMID 8822126.

[pmid10549720-2] Lassen MR, Backs S, Borris LC, Kaltoft-Sørenson M, Coff-Ganes H, Jeppesen E (1999). "Deep-vein thrombosis prophylaxis in orthopedic surgery: hip surgery". Semin. Thromb. Hemost. 25 Suppl 3: 79–82. PMID 10549720.

[pmid15887830-3] Gore M, Kelkar P, Rege N, Ross C (October 2004). "Reviparin sodium clivarine: a review of its therapeutic use". J Indian Med Assoc. 102 (10): 589–90, 592. PMID 15887830.

[pmid8180331-4] Preisack MB, Karsch KR (December 1993). "Experimental and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary angioplasty". Blood Coagul. Fibrinolysis. 4 Suppl 1: S55–8, discussion S59–60. PMID 8180331.

[pmid8917255-5] Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R (November 1996). "Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation". J. Am. Coll. Cardiol. 28 (6): 1437–43. doi:10.1016/s0735-1097(96)00343-9. hdl:1765/55740. PMID 8917255.

[1]

[2]

[3]

[4]

[5]

@@ Line 1: / Line 1: @@
+{{Short description|Pharmaceutical drug}}
 {{Drugbox
 | Verifiedfields = changed
 | verifiedrevid = 447910442
 | IUPAC_name =
+| image = File:Heparin General Structure V.1.svg
-| image =
 <!-- Clinical data -->
 | tradename =
@@ Line 29: / Line 30: @@
 | ATC_prefix = B01
 | ATC_suffix = AB08
 | PubChem =
 | DrugBank_Ref = {{drugbankcite|correct|drugbank}}
-| DrugBank =
+| DrugBank = DB09259
 | KEGG_Ref = {{keggcite|changed|kegg}}
 | KEGG = D03337
@@ Line 42: / Line 43: @@
 '''Reviparin''' is an [[antithrombotic]] and belongs to the group of [[low molecular weight heparin]]s (LMWH).
-== Pharmacodynamic ==
+== Medical uses ==
-Reviparin is a low molecular weight heparin obtained by [[nitrous acid]] depolymerization of heparin extracted from porcine intestinal mucosa. Its structure is characterized, for the most part, by a group of 2-''O''-sulfo-α-lidopyranosuronic acid. The average molecular weight is about 3900 [[dalton (unit)|daltons]].
-== Indications ==
 * [[Thrombosis prevention|Prevention of blood clots]]
-* Prophylaxis of perioperative [[thromboembolism]]<ref name="pmid8822126">{{cite journal |vauthors=Kakkar VV, Cohen AT, Mohamed MS |title=Patients at risk of venous thromboembolism--clinical results with reviparin |journal=Thromb. Res. |volume=81 |issue=2 Suppl |pages=S39–45 |year=1996 |pmid=8822126 |doi=10.1016/0049-3848(95)00228-6  |url= }}<!--|accessdate=2014-09-18--></ref><ref name="pmid10549720">{{cite journal |vauthors=Lassen MR, Backs S, Borris LC, Kaltoft-Sørenson M, Coff-Ganes H, Jeppesen E |title=Deep-vein thrombosis prophylaxis in orthopedic surgery: hip surgery |journal=Semin. Thromb. Hemost. |volume=25 Suppl 3 |issue= |pages=79–82 |year=1999 |pmid=10549720 |doi= |url= }}<!--|accessdate=2014-09-18--></ref>
+* Prophylaxis of perioperative [[thromboembolism]]<ref name="pmid8822126">{{cite journal |vauthors=Kakkar VV, Cohen AT, Mohamed MS |title=Patients at risk of venous thromboembolism--clinical results with reviparin |journal=Thromb. Res. |volume=81 |issue=2 Suppl |pages=S39–45 |year=1996 |pmid=8822126 |doi=10.1016/0049-3848(95)00228-6  }}<!--|access-date=2014-09-18--></ref><ref name="pmid10549720">{{cite journal |vauthors=Lassen MR, Backs S, Borris LC, Kaltoft-Sørenson M, Coff-Ganes H, Jeppesen E |title=Deep-vein thrombosis prophylaxis in orthopedic surgery: hip surgery |journal=Semin. Thromb. Hemost. |volume=25 Suppl 3 |pages=79–82 |year=1999 |pmid=10549720 }}<!--|access-date=2014-09-18--></ref>
-* Treatment of DVT with or without [[pulmonary embolism]] (PE)<ref name="pmid15887830">{{cite journal |vauthors=Gore M, Kelkar P, Rege N, Ross C |title=Reviparin sodium clivarine: a review of its therapeutic use |journal=J Indian Med Assoc |volume=102 |issue=10 |pages=589–90, 592 | date=October  2004 |pmid=15887830 |doi= |url= }}<!--|accessdate=2014-09-18--></ref>
+* Treatment of DVT with or without [[pulmonary embolism]] (PE)<ref name="pmid15887830">{{cite journal |vauthors=Gore M, Kelkar P, Rege N, Ross C |title=Reviparin sodium clivarine: a review of its therapeutic use |journal=J Indian Med Assoc |volume=102 |issue=10 |pages=589–90, 592 | date=October 2004 |pmid=15887830 }}<!--|access-date=2014-09-18--></ref>
-* Prophylaxis of acute thrombotic events after [[percutaneous transluminal coronary angioplasty]] (PTCA)<ref name="pmid8180331">{{cite journal |vauthors=Preisack MB, Karsch KR |title=Experimental and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary angioplasty |journal=Blood Coagul. Fibrinolysis |volume=4 Suppl 1 |issue= |pages=S55–8; discussion S59–60 | date=December  1993 |pmid=8180331 |doi= |url= }}<!--|accessdate=2014-09-18--></ref><ref name="pmid8917255">{{cite journal |vauthors=Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R |title=Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation |journal=J. Am. Coll. Cardiol. |volume=28 |issue=6 |pages=1437–43 | date=November  1996 |pmid=8917255 |doi= 10.1016/s0735-1097(96)00343-9|url=http://linkinghub.elsevier.com/retrieve/pii/S0735109796003439 |accessdate=2014-09-18}}</ref>
+* Prophylaxis of acute thrombotic events after [[percutaneous transluminal coronary angioplasty]] (PTCA)<ref name="pmid8180331">{{cite journal |vauthors=Preisack MB, Karsch KR |title=Experimental and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary angioplasty |journal=Blood Coagul. Fibrinolysis |volume=4 Suppl 1 |pages=S55–8; discussion S59–60 | date=December 1993 |pmid=8180331 }}<!--|access-date=2014-09-18--></ref><ref name="pmid8917255">{{cite journal |vauthors=Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R |title=Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation |journal=J. Am. Coll. Cardiol. |volume=28 |issue=6 |pages=1437–43 | date=November 1996 |pmid=8917255 |doi= 10.1016/s0735-1097(96)00343-9|hdl=1765/55740 |url=http://repub.eur.nl/pub/55740 |hdl-access=free }}</ref>
+== Chemistry ==
+Reviparin is a low molecular weight heparin obtained by [[nitrous acid]] depolymerization of heparin extracted from porcine intestinal mucosa. Its structure is characterized, for the most part, by a group of 2-''O''-sulfo-α-lidopyranosuronic acid. The average molecular weight is about 3900 [[dalton (unit)|daltons]].
 ==References==
@@ Line 56: / Line 57: @@
 ==External links==
 * {{MeshName|reviparin}}
-* {{cite journal  |vauthors=Yusuf S, Mehta SR, Xie C, etal |title=Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation |journal=JAMA |volume=293 |issue=4 |pages=427–35 |year=2005 |pmid=15671427 |doi=10.1001/jama.293.4.427}}
+* {{cite journal  |vauthors=Yusuf S, Mehta SR, Xie C, etal |title=Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation |journal=JAMA |volume=293 |issue=4 |pages=427–35 |year=2005 |pmid=15671427 |doi=10.1001/jama.293.4.427|doi-access=free }}
 {{Antithrombotics}}